Background

Surgical resection has established itself as the standard treatment for early-stage Non-Small Cell Lung Cancer (NSCLC), offering the possibility of a cure. However, many patients cannot undergo surgery due to advanced age or underlying conditions such as impaired cardiopulmonary function. In clinical practice, Stereotactic Body Radiotherapy (SBRT), which precisely delivers high-dose radiation to tumor cells, has been established as the standard of care for these inoperable patients.

Despite the excellent local control rates of SBRT, significant rates of distant metastasis or in-field recurrence have been reported during long-term follow-up, creating a high unmet need. Because preclinical evidence has accumulated suggesting that radiation induces cancer cell death and exposes neoantigens in the tumor microenvironment, triggering a systemic immune response, there were high expectations for combining it with immune checkpoint inhibitors. Efforts to advance PD-L1 inhibitors, which have become standard treatment for metastatic and locally advanced lung cancer, to earlier stages to improve cure rates have led to large collaborative Phase 3 clinical trials.

Key Findings

This clinical trial is the first large-scale multicenter Phase 3 study to evaluate the efficacy of adding immunotherapy in patients with inoperable early-stage NSCLC. Researchers directly compared a group receiving SBRT alone with a group receiving SBRT combined with the immune checkpoint inhibitor Atezolizumab through randomization.

Final analysis showed that the primary endpoint, Overall Survival (OS), did not demonstrate statistical superiority for the combination therapy. Adding immunotherapy to radiation therapy did not significantly reduce the risk of death, and no significant gap emerged between the survival curves.

In terms of safety indicators, the burden on the combination group was notably increased. The incidence of Grade 3 or higher severe adverse events was significantly higher in the atezolizumab combination group. In particular, given the characteristics of this patient population, where there is a persistent risk of combined radiation pneumonitis and immune-mediated pneumonitis, it was observed that the toxicity risk associated with the additional medication outweighed the efficacy benefits.

Implications and Outlook

It has been confirmed that the immune-radiation synergy model proven in metastatic cancers does not unconditionally transfer to the local treatment environment of early NSCLC. This result reveals a clinical gap where the positive immune response induction observed in preclinical animal models and small-scale early clinical trials does not directly translate to long-term survival extension in actual patients.

The fact that most patients with inoperable early-stage lung cancer are a group already suffering from underlying respiratory diseases or frailty is also a significant explanatory factor. It has been suggested that the expected anti-tumor effects may have been offset because these patients lacked the physiological reserve to withstand the additional toxicity from immunotherapy.

Future research must shift toward a precision strategy, avoiding indiscriminate systemic combination therapy and instead selecting sub-populations with extremely high recurrence risks using molecular biomarkers such as tumor mutation burden (TMB) or circulating tumor DNA (ctDNA). This serves as a turning point that reaffirms that in a local treatment environment aimed at a cure, the balance between efficacy and toxicity management must be more strictly maintained than anything else.